Replies to post #3921 on Halozyme Therapeutics Inc (HALO)

[friendofthedevil]

Don't understand that either. In the US, at least, despite what others have suggested, that shouldn't be a huge factor.

It was noted that Europe's first biosimilars for Her and Mab are late 2017. I believe the implication was that Roche had that long to convert substantial market share to SQ.